These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The case for preemption of prescription drug failure-to-warn claims. Kim CH Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969 [No Abstract] [Full Text] [Related]
7. Impossible? Outlawing state safety laws for generic drugs. Glantz LH; Annas GJ N Engl J Med; 2011 Aug; 365(8):681-3. PubMed ID: 21830958 [No Abstract] [Full Text] [Related]
8. The impact of Wyeth v. Levine on FDA regulation of prescription drugs. Ausness RC Food Drug Law J; 2010; 65(2):247-83, i-ii. PubMed ID: 24475542 [TBL] [Abstract][Full Text] [Related]
9. PLIVA v. Mensing: generic consumers' unfortunate hand. Lee SB Yale J Health Policy Law Ethics; 2012; 12(2):209-63. PubMed ID: 23175916 [No Abstract] [Full Text] [Related]
10. On access and accountability--two Supreme Court rulings on generic drugs. Boumil MM; Curfman GD N Engl J Med; 2013 Aug; 369(8):696-7. PubMed ID: 23923990 [No Abstract] [Full Text] [Related]
11. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate. Dorfman HL; Quinn VM; Brophy EA Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765 [No Abstract] [Full Text] [Related]
12. Good law from tragic facts--Congress, the FDA, and preemption. Annas GJ N Engl J Med; 2009 Sep; 361(12):1206-11. PubMed ID: 19759383 [No Abstract] [Full Text] [Related]
13. Prescription for fairness: a new approach to tort liability of brand-name and generic drug manufacturers. Rostron A Duke Law J; 2011 Feb; 60(5):1123-91. PubMed ID: 21365961 [TBL] [Abstract][Full Text] [Related]
14. Should preemption apply in a pharmaceutical context? An analysis of the preemption debate and what regulatory compliance statutes contribute to the discussion. Surprenant JA Fordham Law Rev; 2008 Oct; 77(1):327-63. PubMed ID: 18982554 [TBL] [Abstract][Full Text] [Related]
15. The Supreme Court's Latest Ruling on Drug Liability and its Implications for Future Failure-to-Warn Litigation. Morten CJ; Kesselheim AS; Ross JS J Law Med Ethics; 2019 Dec; 47(4):783-787. PubMed ID: 31957583 [No Abstract] [Full Text] [Related]
16. Permitting product liability litigation for FDA-approved drugs and devices promotes patient safety. Kesselheim AS Clin Pharmacol Ther; 2010 Jun; 87(6):645-7. PubMed ID: 20485322 [TBL] [Abstract][Full Text] [Related]
17. Court rules generic drug companies not responsible for adverse outcomes. Kouros N Monash Bioeth Rev; 2013 Sep; 31(2):23-4. PubMed ID: 24844072 [No Abstract] [Full Text] [Related]
18. The learned intermediary doctrine and patient package inserts: a balanced approach to preventing drug-related injury. Paytash CA Stanford Law Rev; 1999 May; 51(5):1343-71. PubMed ID: 10558426 [TBL] [Abstract][Full Text] [Related]
19. Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health. Gostin LO JAMA; 2009 May; 301(19):2036-7. PubMed ID: 19454642 [No Abstract] [Full Text] [Related]